双环醇是由我国自主研发、用于治疗肝脏炎性损伤的首个化学新药。双环醇上市后，在多种病因所致肝病的抗炎保肝治疗中积累了大量的基础研究和循证医学证据。基础研究方面，双环醇在化学性、免疫性、脂肪性、纤维化及肝部分切除与缺血再灌注等肝功能损伤模型中呈现了抗炎保肝作用及相关分子机制。临床应用方面，多项临床研究评价了双环醇用于治疗慢性病毒性肝炎、脂肪性肝病、多种药物所致药物性肝损伤以及其他肝病的疗效和安全性。真实世界大样本数据分析进一步表明了双环醇具有良好的安全性。本《双环醇临床应用专家共识》根据近5年来双环醇治疗肝脏炎性损伤不断积累的循证医学证据和基础研究结果，对2014年《双环醇片临床应用专家建议》进行修订和完善，以期为临床医生提供更为科学、严谨、全面和实用的双环醇用药参考意见，更好地服务于临床实践。

Bicyclol was the first chemical new drug independently developed by China and used to treat inflammatory liver injury. After bicyclol was put on the market, a large amount evidences of basic researches and evidence-based medicine had been accumulated in the anti-inflammatory and hepatoprotective treatment of liver diseases caused by various causes. In the aspect of basic research, bicyclol had showed the anti-inflammatory and hepatoprotective effects and related molecular mechanisms in models such as the chemical, immune, fatty and fibrotic liver injury and partial liver resection and ischemia-reperfusion injury. In terms of clinical application, several clinical studies had evaluated the efficacy and safety of bicyclol in the treatment of chronic viral hepatitis, fatty liver disease, drug-induced liver injury and other liver diseases. Analysis of large sample data in the real world furtherly showed that bicyclol had good security. According to the evidence-based medical evidence and basic research results accumulated by bicyclol in the treatment of liver inflammatory injury in the past five years, the "Expert recommendations on clinical application of bicyclol tablets" in 2014 was revised and improved. Then this "Expert consensus on clinical application of bicyclol" is formed in order to provide clinicians with more scientific, rigorous, comprehensive and practical reference opinions on the administration of bicyclol, so as to better serve the clinical practice.